Johnson & Johnson JNJ Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales to customers (Note 9) by Business | ||||||
| Innovative Medicine | $15.43B+11.2% | $15.76B+10.0% | $15.56B+6.7% | $15.2B+4.9% | $13.87B+2.3% | |
| MEDTECH | $8.64B+7.7% | $8.8B+7.5% | $8.43B+6.8% | $8.54B+7.3% | $8.02B+2.5% | |
| Other (income) expense, net by Business | ||||||
| Innovative Medicine | -$12M+92.8% | -$193M+4.0% | -$368M-137% | $14M-65.9% | -$166M-49.5% | |
| MEDTECH | $76M+227% | $806M+860% | $2M+118% | $190M-17.7% | -$60M-27.7% | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest by Business | ||||||
| Innovative Medicine | $5.32B+2.1% | $5.06B+26.2% | $6.45B+43.8% | $5.55B+1.7% | $5.21B+4.9% | |
| MEDTECH | $1.24B-12.8% | $201M+179% | $1.29B+21.5% | $1.2B+10.6% | $1.42B-6.5% | |
| Total Assets by Business | ||||||
| General Corporate | $36.6B-26.6% | $34.67B-10.4% | $31.89B— | $31.16B— | $49.83B— | |
| Innovative Medicine | $78.12B+33.0% | $78.06B+36.8% | $74.42B— | $75.49B— | $58.73B— | |
| MEDTECH | $86.18B+1.3% | $86.48B+2.6% | $86.5B— | $86.75B— | $85.11B— | |
| Cost of products sold by Business | ||||||
| Innovative Medicine | $4.39B+9.2% | $3.98B+13.1% | $3.67B+3.5% | $3.98B+10.4% | $4.02B+19.3% | |
| MEDTECH | $3.7B+11.3% | $3.97B+10.5% | $3.61B+6.8% | $3.64B+12.0% | $3.33B+6.6% | |
| Depreciation and Amortization by Business | ||||||
| General Corporate | $65M+25.0% | $70M+12.9% | $59M-38.5% | $60M-52.4% | $52M-10.3% | |
| Innovative Medicine | $1.04B+17.2% | $1.02B+5.0% | $832M-10.7% | $1.04B+22.5% | $884M-12.6% | |
| MEDTECH | $903M+8.0% | $926M+6.8% | $886M+8.3% | $842M+4.5% | $836M+12.1% | |
| Selling, marketing and administrative expenses by Business | ||||||
| Innovative Medicine | $2.92B+29.1% | $3.46B+4.3% | $2.87B+15.2% | $2.79B+4.7% | $2.26B-7.3% | |
| MEDTECH | $2.91B+9.4% | $3.04B+7.0% | $2.8B+2.9% | $2.86B+7.2% | $2.66B+2.9% | |
| Research and development expense by Business | ||||||
| Innovative Medicine | $2.81B+10.4% | $3.47B-6.3% | $2.94B-30.1% | $2.87B+5.4% | $2.55B-12.0% | |
| MEDTECH | $714M+5.5% | $786M-50.9% | $728M-1.5% | $647M-9.9% | $677M+4.8% | |
| Additions to Property, Plant & Equipment by Business | ||||||
| General Corporate | $32M-17.9% | $100M+69.5% | $75M+33.9% | $41M-44.6% | $39M-52.4% | |
| Innovative Medicine | $508M+84.1% | $910M+23.1% | $479M+14.6% | $411M+28.0% | $276M+19.0% | |
| MEDTECH | $509M+6.0% | $827M+1.6% | $603M+8.6% | $591M+1.7% | $480M-2.6% | |
| Goodwill, Written off Related to Sale of Business Unit by Business | ||||||
| Innovative Medicine | $0— | $0— | $0— | $0— | $0— | |
| MEDTECH | $0-100% | —— | —— | —— | $29M— | |
| Percent Change (as a percent) by Business | ||||||
| Innovative Medicine | 32%+9.7pp | 0.9%+10.1pp | 21.3%+2.6pp | 24%+8.3pp | 22.3%+70.6pp | |
| MEDTECH | 18.5%+2.1pp | —— | 21.2%-5.0pp | 23.5%+7.9pp | 16.4%-6.6pp | |
| Goodwill (Note 3) by Business | ||||||
| Innovative Medicine | $14.81B+35.8% | $14.97B+40.0% | $14.27B+28.4% | $14.33B+33.0% | $10.91B+3.4% | |
| MEDTECH | $33.75B+0.6% | $33.81B+0.9% | $33.78B+0.3% | $33.79B+0.9% | $33.56B+28.8% | |
| Currency translation/Other by Business | ||||||
| Innovative Medicine | -$155M-172% | $57M+113% | $0-100% | $543M+1,053% | $215M+248% | |
| MEDTECH | -$59M-172% | $25M+114% | $0-100% | $230M+1,250% | $82M+194% | |
| Goodwill, related to acquisitions by Business | ||||||
| Innovative Medicine | $0— | $642M+3,110% | $0-100% | $2.88B+953% | $0-100% | |
| MEDTECH | $0— | $0-100% | $0-100% | $0-100% | $0— | |
| Amortization by Business | ||||||
| Innovative Medicine | $800M+33.3% | —— | $600M-14.3% | $800M+14.3% | $600M-14.3% | |
| MEDTECH | $500M0.0% | —— | $500M0.0% | $500M+25.0% | $500M+25.0% | |
| Sales to customers (Note 9) by Product | ||||||
| ADVANCED | $1.12B+4.7% | $1.18B+2.1% | $1.17B+5.0% | $1.16B+2.0% | $1.07B-1.3% | |
| CAPLYTA | $270M— | $249M— | $240M— | $211M— | $0— | |
| CARVYKTI | $597M+61.8% | $555M+66.2% | $524M+83.2% | $439M+136% | $369M+135% | |
| CONCERTA/Methylphenidate | $136M-8.1% | $132M-17.0% | $140M-1.4% | $164M+0.6% | $148M-16.4% | |
| CONTACT LENSES / OTHER | $969M+5.4% | $1.01B+7.6% | $1.02B+5.2% | $965M+5.1% | $919M+1.0% | |
| DARZALEX | $3.96B+22.5% | $3.9B+26.6% | $3.67B+21.8% | $3.54B+23.0% | $3.24B+20.2% | |
| EDURANT/rilpivirine | $409M+14.2% | $383M+18.9% | $385M+16.7% | $360M+21.2% | $358M+10.8% | |
| ERLEADA | $949M+23.1% | $959M+22.3% | $936M+18.5% | $908M+23.4% | $771M+11.9% | |
| GENERAL | $1.39B+4.9% | $1.47B+8.2% | $1.38B+4.0% | $1.39B+3.3% | $1.32B-0.5% | |
| HIPS | $436M+6.6% | $439M+5.0% | $405M+6.3% | $421M+1.0% | $409M-3.1% | |
| IMBRUVICA | $660M-6.9% | $684M-6.4% | $695M-7.7% | $735M-4.5% | $709M-9.6% | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | $1.04B+15.0% | $986M-7.2% | $929M-11.4% | $992M-5.9% | $903M-14.5% | |
| KNEES | $420M+8.0% | $432M+8.5% | $377M+7.1% | $389M-1.3% | $389M-3.0% | |
| OPSUMIT/OPSYNVI | $606M+16.1% | —— | $578M-0.9% | $582M+6.2% | $522M-0.4% | |
| OTHER IMMUNOLOGY | $46M+4,500% | $40M— | $12M+1,100% | $8M+300% | $1M— | |
| OTHER INFECTIOUS DISEASES | $37M-9.8% | $40M-11.1% | $47M-16.1% | $47M-79.8% | $41M-47.4% | |
| OTHER NEUROSCIENCE | $262M-5.4% | $245M-3.9% | $256M-8.9% | $270M-8.2% | $277M-19.7% | |
| Other Oncology | $192M-10.3% | $100M+33.3% | $94M+9.3% | $93M+12.0% | $214M+193% | |
| Other | $2.9B+2.1% | $249M-11.4% | $264M-9.6% | $309M+1.3% | $2.84B+813% | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | $443M+9.9% | $383M-5.9% | $397M-11.6% | $396M-9.6% | $403M-3.6% | |
| Remicade | $422M-9.6% | $370M+3.1% | $476M+13.6% | $455M+15.8% | $467M+7.6% | |
| RYBREVANT + LAZCLUZE | $257M+82.3% | $216M+77.0% | $198M+122% | $179M+159% | $141M+200% | |
| SIMPONI / SIMPONI ARIA | $647M-1.8% | $632M+8.4% | $687M+33.1% | $690M+28.5% | $659M+19.0% | |
| SPINE & OTHER | $694M+3.4% | —— | $698M+0.3% | $727M-2.2% | $671M-10.8% | |
| SPRAVATO | $468M+46.3% | $503M+69.4% | $459M+61.6% | $414M+52.8% | $320M+42.2% | |
| STELARA | $656M-59.6% | $1.23B-47.6% | $1.57B-41.3% | $1.65B-42.7% | $1.63B-33.7% | |
| SURGICAL | $396M+9.7% | $411M+12.6% | $383M+15.0% | $403M+9.8% | $361M+3.7% | |
| TALVEY | $152M+76.7% | $149M+75.3% | $122M+62.7% | $106M+53.6% | $86M+48.3% | |
| Tecvayli | $202M+33.8% | $176M+20.5% | $177M+31.1% | $166M+23.0% | $151M+13.5% | |
| TRAUMA | $833M+7.9% | $813M+6.4% | $793M+4.2% | $768M+1.2% | $772M+0.9% | |
| Tremfya | $1.61B+68.2% | $1.59B+67.4% | $1.42B+41.4% | $1.19B+30.9% | $956M+18.3% | |
| UPTRAVI | $483M+7.1% | $491M+5.6% | $484M+5.7% | $476M+11.7% | $451M-3.6% | |
| XARELTO | $642M-7.0% | $687M+1.6% | $635M+7.3% | $621M+5.8% | $690M+33.2% | |
| Percent Change (as a percent) by Product | ||||||
| ADVANCED | 4.6%+5.8pp | 0.1%— | 5%+9.7pp | 2%+8.7pp | -1.2%+1.6pp | |
| CAPLYTA | 0%— | 0%— | 0%— | 0%— | 0%— | |
| CARVYKTI | 62.1%— | 6.3%-2.1pp | 83.5%-4.2pp | —— | —— | |
| CONCERTA/Methylphenidate | -8%+8.3pp | -2.7%— | -1.4%+23.4pp | 0.2%+21.7pp | -16.3%-2.2pp | |
| CONTACT LENSES / OTHER | 5.5%+4.5pp | 1%-0.7pp | 5.2%+1.0pp | 5.1%+7.3pp | 1%+5.6pp | |
| DARZALEX | 22.5%+2.2pp | 1.3%+0.8pp | 21.7%+1.0pp | 23%+4.6pp | 20.3%+1.4pp | |
| EDURANT/rilpivirine | 14.1%+3.4pp | 0.8%— | 16.4%+4.9pp | 21.6%+10.6pp | 10.7%-5.0pp | |
| ERLEADA | 23.1%+11.2pp | 1.2%— | 18.4%-7.0pp | 23.4%-6.4pp | 11.9%-15.1pp | |
| GENERAL | 4.9%+5.4pp | 1.5%+1.7pp | 3.9%+3.1pp | 3.3%+5.2pp | -0.5%-1.5pp | |
| HIPS | 6.5%+9.6pp | 0.8%— | 6.4%+4.7pp | 1%-3.9pp | -3.1%-11.2pp | |
| IMBRUVICA | -6.9%+2.6pp | —— | -7.8%-1.0pp | -4.5%+4.0pp | -9.5%-4.3pp | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | 15%+29.5pp | —— | -11.3%-13.2pp | -5.9%-8.1pp | -14.5%-15.7pp | |
| KNEES | 7.9%+10.9pp | 2%— | 7%+3.0pp | -1.1%-9.5pp | -3%-12.0pp | |
| OPSUMIT/OPSYNVI | 16.1%+16.6pp | —— | -0.8%— | 6.4%— | -0.5%— | |
| OTHER INFECTIOUS DISEASES | -10.4%+37.2pp | —— | -17.5%+7.9pp | -79.8%-56.7pp | -47.6%-12.5pp | |
| OTHER NEUROSCIENCE | -5.4%+14.2pp | —— | -8.9%+8.5pp | -8.4%+15.3pp | -19.6%-1.1pp | |
| Other Oncology | -10.6%-32.3pp | 4.5%+101pp | 9.7%-15.1pp | 11.7%-72.5pp | 21.7%-58.5pp | |
| Other | -27.8%-20.6pp | —— | -13.1%-28.1pp | -16.9%-24.1pp | -7.2%+12.3pp | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | 10%+13.7pp | —— | -11.6%-12.2pp | -9.4%+1.6pp | -3.7%+8.6pp | |
| Remicade | -9.5%-17.0pp | —— | 13.6%+22.7pp | 15.9%+30.8pp | 7.5%+18.4pp | |
| RYBREVANT + LAZCLUZE | 82.7%— | —— | 99.7%— | —— | —— | |
| SIMPONI / SIMPONI ARIA | -1.7%-20.6pp | —— | 32.9%+50.9pp | 28.6%+27.0pp | 18.9%+15.9pp | |
| SPINE & OTHER | 3.5%+14.3pp | —— | 0.3%+2.2pp | -2.1%+1.0pp | -10.8%-14.0pp | |
| SPRAVATO | 46.4%+4.5pp | 4.4%— | 61.5%+6.6pp | 53.3%-6.9pp | 41.9%-30.3pp | |
| STELARA | -59.7%-26.0pp | -1.8%+1.6pp | -41.3%-34.7pp | -42.7%-45.8pp | -33.7%-34.0pp | |
| SURGICAL | 9.7%+6.0pp | 0.8%-2.1pp | 14.9%+13.6pp | 9.9%+10.4pp | 3.7%+3.4pp | |
| TALVEY | 76.7%+28.3pp | 6%— | 60.8%— | 55%— | 48.4%— | |
| Tecvayli | 33.5%+20.2pp | —— | 31.3%+10.7pp | 23.1%-19.8pp | 13.3%-63.4pp | |
| TRAUMA | 8%+7.1pp | 1.1%+0.9pp | 4.2%+1.6pp | 1.2%-1.6pp | 0.9%-0.1pp | |
| Tremfya | 68.3%+50.1pp | 9.5%— | 41.3%+28.3pp | 31%+2.7pp | 18.2%-8.1pp | |
| UPTRAVI | 7.1%+10.7pp | 0.4%— | 5.6%-8.6pp | 11.7%+5.1pp | -3.6%-32.8pp | |
| XARELTO | -7%-40.3pp | —— | 7.4%+12.6pp | 5.6%+13.5pp | 33.3%+43.7pp | |
| Sales to customers (Note 9) by Geography | ||||||
| Asia-Pacific, Africa | $3.59B+8.5% | $3.5B+7.4% | $3.61B+4.0% | $3.61B+4.5% | $3.31B-2.8% | |
| Europe | $5.85B+14.4% | $5.6B+13.8% | $5.44B+10.7% | $5.39B+3.3% | $5.11B-1.0% | |
| United States | $13.33B+8.3% | $14.2B+7.5% | $13.71B+6.2% | $13.54B+7.8% | $12.31B+5.9% | |
| Western Hemisphere, excluding U.S. | $1.29B+10.8% | $1.27B+12.0% | $1.23B+4.9% | $1.21B-0.5% | $1.17B-2.3% | |
| Percent Change by Geography | ||||||
| Asia-Pacific, Africa | 8.5%+11.3pp | —— | 4%+3.5pp | 4.4%+8.4pp | -2.8%-1.7pp | |
| Europe | 14.5%+15.5pp | —— | 10.7%+6.7pp | 3.3%+1.7pp | -1%+6.6pp | |
| United States | 8.3%+2.4pp | —— | 6.2%-1.4pp | 7.8%0.0pp | 5.9%-1.9pp | |
| Western Hemisphere, excluding U.S. | 10.8%+13.1pp | —— | 4.9%+4.6pp | -0.5%-7.2pp | -2.3%-13.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Johnson & Johnson break its business down?
- Johnson & Johnson (JNJ) reports sales to customers (note 9) by business across 2 parts — Innovative Medicine and MEDTECH. Each is extracted from the segment footnotes and tracked over time.
- Where does Johnson & Johnson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Johnson & Johnson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
